Supernus Corp (SUPN): מקדם מחיר להכנסות

Stable distribution channels eliminate supply disruptions for neuropreparations for Supernus Pharmaceuticals (SUPN). The estimated price-to-sales ratio visualizes the market valuation of assets, where the 2.70 level represents the current value. Market share protection is based on unique substance-release formulas. High scalability is ensured through subsequent global commercialization of products following successful clinical trials.

For Supernus Pharmaceuticals (SUPN), whose revenues depend on long-term contracts with healthcare systems for the supply of CNS therapy drugs, the P/S levels on this chart reflect the market value of one dollar of revenue. The ratio of market capitalization to sales allows for an assessment of the premium paid for the business, where low values create a defensive buffer and high values increase the risk of a correction during a trend reversal.